Leading Innovation in
GLP-1 Treatment for Addiction

Caron’s GLP-1 pilot program represents an important emerging advancement in addiction treatment, offering a new way to address the underlying biology of craving.

Unlike traditional medications that target a single substance, GLP-1s act on the brain’s dopamine reward system—the pathway that drives both substance use and behavioral addictions. By reducing the intensity of reward signals and quieting trigger responses, these medications may help decrease the mental preoccupation that keeps many individuals stuck.

GLP-1 treatment is not a cure, and it is not a replacement for therapy. At Caron Treatment Centers, it is integrated into a comprehensive, individualized treatment plan that supports deeper healing, stronger engagement in treatment, and long-term recovery.

What Are GLP-1 Medications?

GLP-1 receptor agonists were originally developed to treat diabetes and obesity. Emerging research and early clinical experience suggest these medications may also reduce cravings by acting on the brain’s dopamine reward system—the central pathway involved in both substance and behavioral addictions.

Unlike traditional medications that target a specific substance, GLP-1s work at the level of reward circuitry itself. This broader mechanism positions them as a potential cross-addiction tool, expanding the limited medication options currently available in addiction medicine.

Who May Benefit From GLP-1 Treatment?

• GLP-1 medications are not a cure-all and are not appropriate for every patient.
• At Caron, we consider GLP-1 treatment for individuals who: 
  • Continue to feel overwhelmed by cravings despite comprehensive treatment
  • May benefit from additional biological support alongside therapy
  • Have not achieved desired outcomes with traditional medication-assisted treatment

These medications are used selectively when the risks and benefits are appropriate, given the patient’s clinical profile. GLP-1s are always paired with a robust, individualized treatment plan that supports, not replaces, psychological, and trauma-informed care.

A Science-Driven, Human-Centered Approach

Our GLP-1 pilot program is led by physicians trained in psychiatry, internal medicine, and addiction medicine who understand how untreated addiction drives crisis and suffering. 

GLP-1s represent an opportunity to shift the underlying biology of craving in a way patients can feel, allowing them to engage more fully in the work of recovery. 

National Attention on GLP-1s in Addiction Treatment

Caron’s work with GLP-1 medications has received national media attention, including coverage by:

Is GLP-1 Treatment Right for You or a Loved One? 

If you or someone you love is struggling with persistent cravings despite comprehensive treatment, our team can help determine whether GLP-1 therapy may be an appropriate addition to a personalized recovery plan.

Contact Caron today to learn more about our GLP-1 pilot program and full continuum of care. 

GLP-1 medications are FDA-approved for the treatment of diabetes and obesity. Their use in substance use disorder is considered off-label and is based on emerging research and clinical evaluation.

Caron's Team is Leading the Innovation in GLP-1 Treatment for Addiction